AXSM - ROSEN SKILLED INVESTOR COUNSEL Encourages Axsome Therapeutics Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM | Benzinga
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) --
WHY: Rosen Law Firm, a global investor rights law firm, announces the reopening of the lead plaintiff appointment process in a class action lawsuit against Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ:AXSM) and certain of its officers. The Class Action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-03925 (LGS), is proposed to be brought on behalf of a Class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Axsome common stock between May 10, 2021 and April 22, 2022, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws. Excluded from the proposed Class will be any persons who sold all of the shares acquired during the Class Period prior to April 25, 2022. If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2023.
SO WHAT: If you purchased Axsome common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Axsome class action, go to https://rosenlegal.com/submit-form/?case_id=2221 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move ...